Researchers are studying a medicine called MK-8527 to learn how it behaves in the body of healthy adults.
The goal of this study is to learn about the effect of MK-8527 when it is taken with food or with other medicines. Researchers also want to learn about the safety of MK-8527 and if people tolerate it. Tolerate means participants will receive treatment in the trial unless they need to stop it due to health problems.
Eligibility
Sex
ALL
Min age
18 Years
Max age
55 Years
Healthy volunteers
Accepted
Inclusion Criteria:
* Be in good health
* Has a body mass index (BMI) between 18 and 32 kg/m\^2, inclusive
Exclusion Criteria:
* Has an estimated glomerular filtration rate (eGFR) ≤90 mL/min/1.73 m\^2
* Has a history of clinically significant endocrine, gastrointestinal (GI), cardiovascular, hematological, hepatic, immunological, renal, respiratory, genitourinary, or major neurological (including stroke and chronic seizures) abnormalities or diseases
* Has a history of stomach or intestinal surgery or resection that would potentially alter absorption and/or excretion of orally administered drugs (uncomplicated appendectomy and hernia repair are allowed)
* Has a history of cancer (malignancy)
* Is taking any medication that contains emtricitabine (FTC) or lamivudine (3TC)
Primary outcome measure(s)
Part 1: Area Under the Concentration Time Curve From Time 0 to Infinity (AUC0-inf) of MK-8527 in Plasma With and Without Food — Predose and at designated timepoints (up to 336 hours postdose) Blood samples will be collected at multiple time points to estimate AUC0-inf of MK-8527 in plasma.
Part 2: AUC0-inf of MK-8527 in Plasma With and Without Probenecid — Predose and at designated timepoints (up to 336 hours postdose) Blood samples will be collected at multiple time points to estimate AUC0-inf of MK-8527 in plasma.
Part 3: AUC0-inf of MK-8527 in Plasma With and Without Itraconazole — Predose and at designated timepoints (up to 336 hours postdose) Blood samples will be collected at multiple time points to estimate AUC0-inf of MK-8527 in plasma.
This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.
We use cookies to analyse site traffic and improve your experience. With your consent, we may also use cookies for advertising. You can change your choice at any time.